Amplitude Inc vs Centene Corp — how do they compare? Amplitude Inc trades at $12.78 (market cap $1.52B), while Centene Corp trades at $66.33 (market cap $32.89B). The key difference: Centene Corp is far larger — about 21.6× Amplitude Inc's market cap. Which is the better fit depends on your goals.
| AMPL | CNC | |
|---|---|---|
Market Cap | $1.52B | $32.89B |
Sector | Technology | Health |
52-Week High | $12.69 | $68.72 |
52-Week Low | $5.61 | $26.17 |
Enterprise Value | $1.39B | $21.93B |
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $11.26, up 4.55% in 24 hours, with a bullish technical signal and strong analyst support. Revenue growth is robust, reaching $343.21 million in 2025, but profitability remains a challenge with a net loss of $88.54 million. Recent news highlights investor conference participation and Q2 2026 results that met revenue estimates but missed on EPS.
The outlook is mixed: strong revenue growth and a $12.08 consensus price target suggest upside, but persistent losses, negative cash flow, and ongoing legal investigations pose significant risks. Investors should weigh growth potential against fundamental weaknesses and sentiment shifts from recent insider sales and legal scrutiny.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →